{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/61cc46b2ea767b0014016ad3?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ebe8cc563e3d811bbd2c9d8/1589546617002-fe8127d1b39ab8ac94a64885bbfaa0ae.jpeg?height=200","description":"<p>During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials?</p><p><br></p><p>In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN trial (NCT02874742) and the CASSIOPEIA trial (NCT02541383).&nbsp;</p>","author_name":"Scientific Education Support"}